C16 Biosciences produces next-generation oils and fats, starting with a sustainable alternative to palm oil, “Palmless”, and palm-derived ingredients developed via precision fermentation of sugars using a wild-type yeast microbe.
C16 Biosciences, located in a 20,000-sq-ft facility in Midtown Manhattan, conducted a 50,000-liter industrial fermentation in November 2022 to develop its commercial-grade product. After introducing its oil (Torula Oil) into beauty products in 2023, the company was working on obtaining approval from the US Food and Drug Administration (as of October 2023) for its use in food products, such as non-dairy ice cream, cheese, bakery products, and pastries.
Funding and financials
In March 2020, the company raised USD 20 million in a Series A funding round led by Breakthrough Energy Ventures to scale its technology and talent acquisition. Further, in October 2023, C16 Biosciences joined Elemental Excelerator and secured USD 1 million to expand its bio-manufactured oil into new food categories, including bakery, dairy, and infant nutrition.
In January 2024 , the company raised USD 4.5 million, comprising of a USD 3.5 million grant from the Bill & Melinda Gates Foundation and a USD 1 million investment from Elemental Excelerator. The funding was earmarked for the expansion of its Palmless platform by harnessing non-agriculturally derived feedstocks to create food-grade oils and fats and hire additional R&D staff.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.